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INVITED EDITORIAL

The Hour for Comparative Effectiveness
Research of Medicines in India
Balkrishnan R1, Patel I2
1) Department of Medicine, University of Virginia, Virginia, USA
2) Department of Biopharmaceutical Sciences, Shenandoah University, Virginia, USA

India is facing many health challenges with increasing
incidence of chronic diseases among the population.
These diseases can be treated or managed with timely
pharmacological treatment. Many of the treatment options
are expensive since after the General Agreement on Tariffs
and Trade (GATT) implementation, newer drugs cannot be
manufactured through process patents. There is a growth
in the health care insurance industry with many employers
offering health care insurance as a benefit to employees
in India. Also many of the local companies that relied on
producing generic equivalents are also entering the global
market where they have to demonstrate value for their
product. Health care payers are all struggling with the costs
of medications. Pharmaceutical companies with dwindling
returns on investments have priced many of the specialty
medications like those used to treat cancer in several lakhs
of rupees per year to recover the cost of R and D in the
relatively small portion of patients who will be using them.
Thus many payers (government, insurance companies and in
some cases patients) want to know the most cost effective way
of treating these conditions considering limited resources at
hand and availability of cheaper pharmacological treatment
options.
In the US, the federal government has been emphasizing the
importance of comparative effectiveness research (CER),
which involves understanding the medication prescribing
and medication utilization among physicians and patients
with chronic diseases. CER can benefit health care policy
making in terms of understanding how physicians and
patients make more informed decisions by knowing patient
health outcomes. CER is defined by the Institute of Medicine
committees as “the generation and synthesis of evidence
that compare the benefits and harms of alternative methods
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to prevent, diagnosis, treat, and monitor a clinical condition
or to improve the delivery of care”1.
CER evaluations should include inputs from stakeholders
such as clinicians, educators, insurers and policy makers
in order to frame questions and translate findings. These
findings should have real world applications in terms of
benefitting the patients or aiding the clinicians in making
better clinical management decisions or helping the research
community to understand the priority placed upon use of a
particular technology over others. Differences in outcomes
such as quality of life, life expectancy, morbidity and mortality
can also be assessed in racial minorities or vulnerable
groups such as children and elderly using prospective or
retrospective CER evaluations2. CER evaluations can boost
innovation by serving as an evidentiary tool for the academic
and public health practitioners as well as medical researchers,
that differentiates cost effective from ‘me too’ technology,
thereby benefitting the populace3. Developing nationally
representative patient registries or claims based databases
that provide patient information, by involving government;
insurers and healthcare providers can aid successful CER
evaluations. Matching patient registries with medical claims
data can provide strong evidence about the quality of care
that patients receive since registries provide information
about clinical end points that can be complemented with
healthcare utilization information provided by the claims
dataset4.
The growth of pharmacy education in India is producing
many graduates with advanced knowledge of the
effectiveness of medication therapies. This new generation
of pharmacy professionals can lead the way in conducting
these timely CERs so that we can address issues such as cost
effectiveness and access to medications that are essential
and potentially life-saving. With the changing demographics
of disease and mortality in India, this is becoming an
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increasingly important issue in making clinical decisions in
treating patients. If conducted and used properly CER has
the ability to allow objective decision making related to the
rational use of pharmaceuticals. Successful CER evaluations
are possible in an environment where healthcare providers,
educators and policy makers can function in collaboration
through sharing of assets, skills and resources that can better
healthcare metrics and bring equity in patient outcomes4.
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